BACKGROUND: Hepatocellular carcinoma (HCC) is a highly vascular tumor which is poorly responsive to standard systemic chemotherapy. Recently, various antiangiogenic targeted agents have shown promising activity at different levels of evidence in patients with advanced HCC, suggesting that such treatments might be effective. CASE REPORT: Since chemotherapy administered with metronomic schedules inhibits angiogenesis, we treated a 64-year-old man with advanced HCC with metronomic capecitabine. After only two months of treatment the HCC nodules disappeared on ultrasonography. This finding was confirmed by a computed tomography scan. After more than three years the patient is still in treatment with minimal toxicity and maintains a complete remission. CONCLUSIONS: Our case report suggests that metronomic capecitabine may be effective in advanced HCC patients while being also well tolerated. This is important, given the frequent comorbidities of HCC patients.
BACKGROUND:Hepatocellular carcinoma (HCC) is a highly vascular tumor which is poorly responsive to standard systemic chemotherapy. Recently, various antiangiogenic targeted agents have shown promising activity at different levels of evidence in patients with advanced HCC, suggesting that such treatments might be effective. CASE REPORT: Since chemotherapy administered with metronomic schedules inhibits angiogenesis, we treated a 64-year-old man with advanced HCC with metronomic capecitabine. After only two months of treatment the HCC nodules disappeared on ultrasonography. This finding was confirmed by a computed tomography scan. After more than three years the patient is still in treatment with minimal toxicity and maintains a complete remission. CONCLUSIONS: Our case report suggests that metronomic capecitabine may be effective in advanced HCC patients while being also well tolerated. This is important, given the frequent comorbidities of HCC patients.
Authors: Giovanni Brandi; Michela Venturi; Stefania De Lorenzo; Francesca Garuti; Giorgio Frega; Andrea Palloni; Ingrid Garajovà; Francesca Abbati; Gioconda Saccoccio; Rita Golfieri; Maria Abbondanza Pantaleo; Maria Aurelia Barbera Journal: Cancer Commun (Lond) Date: 2018-06-26
Authors: Franco Trevisani; Giovanni Brandi; Francesca Garuti; Maria Aurelia Barbera; Raffaella Tortora; Andrea Casadei Gardini; Alessandro Granito; Francesco Tovoli; Stefania De Lorenzo; Andrea Lorenzo Inghilesi; Francesco Giuseppe Foschi; Mauro Bernardi; Fabio Marra; Rodolfo Sacco; Giovan Giuseppe Di Costanzo Journal: J Cancer Res Clin Oncol Date: 2017-12-16 Impact factor: 4.322
Authors: Gauthier Bouche; Nicolas André; Shripad Banavali; Frank Berthold; Alfredo Berruti; Guido Bocci; Giovanni Brandi; Ugo Cavallaro; Saviero Cinieri; Marco Colleoni; Giuseppe Curigliano; Teresa Di Desidero; Alexandru Eniu; Nicola Fazio; Robert Kerbel; Lisa Hutchinson; Urszula Ledzewicz; Elisabetta Munzone; Eddy Pasquier; O Graciela Scharovsky; Yuval Shaked; Jaroslav Stěrba; Martin Villalba; Francesco Bertolini Journal: Ecancermedicalscience Date: 2014-09-09
Authors: Matteo Ravaioli; Alessandro Cucchetti; Antonio Daniele Pinna; Vanessa De Pace; Flavia Neri; Maria Aurelia Barbera; Lorenzo Maroni; Giorgio Frega; Andrea Palloni; Stefania De Lorenzo; Maria Cristina Ripoli; Maria Abbondanza Pantaleo; Matteo Cescon; Massimo Del Gaudio; Giovanni Brandi Journal: Sci Rep Date: 2017-09-12 Impact factor: 4.379